開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

SUCCESSFUL COMPLETION OF PHASE I CLINICAL TRIAL OF GT1708F FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES IN CHINA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that the phase I clinical trial of in-house developed GT1708F (Hedgehog/SMO Inhibitor) for treatment of hematologic malignancies in China (the "**Phase I Clinical Trial**") has been successfully completed. The results showed that GT1708F had demonstrated a good safety and tolerability profile, and all patients experienced no dose-limiting toxicity (the "**DLT**") or drug-related serious adverse events (the "**SAE**"). Preliminary efficacy was observed starting from 180mg dose level in dose escalation stage for patients with acute myeloid leukemia (the "**AML**") who failed multi-line therapies, and the myeloid blasts decreased by up to 62% compared to the baseline in AML patients.

The Phase I Clinical Trial is a study to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of GT1708F for treatment of patients with hematological malignancies, and the main purpose is to evaluate the safety and tolerability of different doses of GT1708F in patients with hematological malignances. Professor Jianxiang Wang（王建祥）and Professor Junyuan Qi（齊軍元）of the Institute of Hematology, Chinese Academy of Medical Sciences are the leading principal investigators (leading PI) of this trial.

A total of 18 patients were enrolled in the trial, including 15 patients with AML and 3 patients with myelodysplastic syndrome ("**MDS**"). The doses and enrollment were 20 mg once daily ("**QD**") (1 case), 40 mg QD (1 case), 80 mg QD (4 cases), 120 mg QD (3 cases), 180 mg QD (3 cases), 240 mg QD (3 cases), and 320 mg QD (3 cases), respectively. The results showed that all patients experienced no DLT or drug-related SAE. The overall safety of each dose group of GT1708F was good, most of the treatment related adverse events ("**TEAE**") were mild, and no TEAE resulting in death occurred.

GT1708F is a SMO protein inhibitor with high activity and specificity, which is in the leading position among drugs with the same target in terms of inhibitory activity. *In vitro* studies showed that its combination use with the AML drug BCL-2 inhibitor has a synergistic effect, and can significantly increase the apoptosis of malignant hematoma cells induced by the latter.

In addition to targeting blood cancer and solid tumors, the latest research and clinical results show that the Hedgehog signaling pathway plays a vital role in idiopathic pulmonary fibrosis ("**IPF**") diseases. At present, there is a huge unmet clinical need in the field of IPF, and there is no effective therapy that can be used to terminate the fibrotic process or cure the disease. Currently, the Company is actively preparing for relevant clinical trial applications for IPF and tumor indications.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT1708F will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 8 May 2023

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*